Background: In China, various assays for human papillomavirus (HPV) genotyping are currently used for cervical cancer screening. However, a proficiency test system is not available for standardizing and evaluating assay performance. The aim of this study was to evaluate the performance of clinical laboratories for their ability to discriminate 9 HPV types with the proficiency panel. Methods: The panel of 24 samples included cloned genomic DNAs for HPV types 6, 11, 16, 18, 31, 33, 39, 51 and 52 at different concentrations, which were distributed to 76 clinical laboratories. Results reported by participants were compared with the reference results. Results: The samples containing 106 IU HPV-16/ml and 106 IU HPV-18/ml were (98.7 and 96.0%, respectively) identified correctly most often. For other high-risk HPV types, about 90% of data sets correctly identified samples containing 106 GE/ml of HPV-6, HPV-31, HPV-33 and HPV-52, while HPV-51, HPV-11 and HPV-39 in 106 GE/ml were correctly identified by only 42.7, 55.6 and 21.3% of laboratories, respectively. Conclusion: Our proficiency test system provided a traceable panel and showed that the differences in performance between laboratories were high, indicating that it is necessary for the laboratories to improve their operation and standardization of HPV genotyping.

Keywords:
Human papillomavirus, Genotyping, Proficiency test, Quality control
1.
Bulkmans NW, Berkhof J, Rozendaal L, van Kemenade FJ, Boeke AJ, Bulk S, Voorhorst FJ, Verheijen RH, van Groningen K, Boon ME, Ruitinga W, van Ballegooijen M, Snijders PJ, Meijer CJ: Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 2007;370:1764-1772.
2.
Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, Snijders PJ, Meijer CJ, International Agency for Research on Cancer Multicenter Cervical Cancer Study Group: Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-527.
3.
Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, Clifford GM: Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007;121:621-632.
4.
Bosch FX, Burchell AN, Schiffman M, Giuliano AR, de Sanjose S, Bruni L, Tortolero-Luna G, Kjaer SK, Muñoz N: Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 2008;26(suppl 10):K1-K16.
5.
Li N, Franceschi S, Howell-Jones R, Snijders PJ, Clifford GM: Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int J Cancer 2011;128:927-935.
6.
Seme K, Fujs K, Kocjan BJ, Poljak M: Resolving repeatedly borderline results of Hybrid Capture 2 HPV DNA Test using polymerase chain reaction and genotyping. J Virol Methods 2006;134:252-256.
7.
Ault KA: Epidemiology and natural history of human papillomavirus infections in the female genital tract. Infect Dis Obstet Gynecol 2006;2006(suppl):40470.
8.
Vandepapeliere P, Barrasso R, Meijer CJ, Walboomers JM, Wettendorff M, Stanberry LR, Lacey CJ: Randomized controlled trial of an adjuvanted human papillomavirus (HPV) type 6 L2E7 vaccine: infection of external anogenital warts with multiple HPV types and failure of therapeutic vaccination. J Infect Dis 2005;192:2099-2107.
9.
Kulasingam SL, Myers ER: Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 2003;290:781-789.
10.
Johnson AM, Mercer CH, Beddows S, de Silva N, Desai S, Howell-Jones R, Carder C, Sonnenberg P, Fenton KA, Lowndes C, Soldan K: Epidemiology of, and behavioural risk factors for, sexually transmitted human papillomavirus infection in men and women in Britain. Sex Transm Infect 2012;88:212-217.
11.
Poljak M, Kocjan BJ: Commercially available assays for multiplex detection of alpha human papillomaviruses. Expert Rev Anti Infect Ther 2010;8:1139-1162.
12.
Kroupis C, Vourlidis N: Human papilloma virus (HPV) molecular diagnostics. Clin Chem Lab Med 2011;49:1783-1799.
13.
Dufresne S, Sauthier P, Mayrand MH, Petignat P, Provencher D, Drouin P, Gauthier P, Dupuis MJ, Michon B, Ouellet S, Hadjeres R, Ferenczy A, Franco EL, Coutlée F: Human papillomavirus (HPV) DNA triage of women with atypical squamous cells of undetermined significance with Amplicor HPV and Hybrid Capture 2 assays for detection of high-grade lesions of the uterine cervix. J Clin Microbiol 2011;49:48-53.
14.
Papachristou E, Sypsa V, Paraskevis D, Gkekas A, Politi E, Nicolaidou E, Anifantis I, Psichogiou M, Tsitsika A, Hadjivassiliou M, Petrikkos G, Katsambas A, Creatsas G, Hatzakis A: Prevalence of different HPV types and estimation of prognostic risk factors based on the linear array HPV genotyping test. J Med Virol 2009;81:2059-2065.
15.
Einstein MH, Martens MG, Garcia FA, Ferris DG, Mitchell AL, Day SP, Olson MC: Clinical validation of the Cervista HPV HR and 16/18 genotyping tests for use in women with ASC-US cytology. Gynecol Oncol 2010;118:116-122.
16.
Eklund C, Forslund O, Wallin KL, Zhou T, Dillner J, WHO Human Papillomavirus Laboratory Network: The 2010 global proficiency study of human papillomavirus genotyping in vaccinology. J Clin Microbiol 2012;50:2289-2298.
17.
Eklund C, Zhou T, Dillner J, WHO Human Papillomavirus Laboratory Network: Global proficiency study of human papillomavirus genotyping. J Clin Microbiol 2010;48:4147-4155.
18.
Zhao R, Zhang WY, Wu MH, Zhang SW, Pan J, Zhu L, Zhang YP, Li H, Gu YS, Liu XZ: Human papillomavirus infection in Beijing, People's Republic of China: a population-based study. Br J Cancer 2009;101:1635-1640.
19.
Wang S, Wei H, Wang N, Zhang S, Zhang Y, Ruan Q, Jiang W, Xiao Q, Luan X, Qian X, Zhang L, Gao X, Sun X: The prevalence and role of human papillomavirus genotypes in primary cervical screening in the northeast of China. BMC Cancer 2012;12:160.
20.
Ye J, Cheng X, Chen X, Ye F, Lü W, Xie X: Prevalence and risk profile of cervical Human papillomavirus infection in Zhejiang Province, southeast China: a population-based study. Virol J 2010;7:66.
21.
Chen Q, Xie LX, Qing ZR, Li LJ, Luo ZY, Lin M, Zhang SM, Chen WZ, Lin BZ, Lin QL, Li H, Chen WP, Zheng PY, Mao LZ, Chen CY, Yang C, Zhan YZ, Liu XZ, Zheng JK, Yang LY: Epidemiologic characterization of human papillomavirus infection in rural Chaozhou, eastern Guangdong Province of China. PLoS One 2012;7:e32149.
22.
Bruni L, Diaz M, Castellsagué X, Ferrer E, Bosch FX, de Sanjosé S: Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis 2010;202:1789-1799.
23.
Ferguson M, Wilkinson DE, Zhou T: WHO meeting on the standardization of HPV assays and the role of the WHO HPV Laboratory Network in supporting vaccine introduction held on 24-25 January 2008, Geneva, Switzerland. Vaccine 2009;27:337-347.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.